BR112013010688A2 - anticorpos anti c-met - Google Patents
anticorpos anti c-metInfo
- Publication number
- BR112013010688A2 BR112013010688A2 BR112013010688A BR112013010688A BR112013010688A2 BR 112013010688 A2 BR112013010688 A2 BR 112013010688A2 BR 112013010688 A BR112013010688 A BR 112013010688A BR 112013010688 A BR112013010688 A BR 112013010688A BR 112013010688 A2 BR112013010688 A2 BR 112013010688A2
- Authority
- BR
- Brazil
- Prior art keywords
- met antibodies
- antibodies
- met
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122014027420-3A BR122014027420A2 (pt) | 2010-11-03 | 2011-11-03 | Anticorpos anti c-met |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40986610P | 2010-11-03 | 2010-11-03 | |
| US61/409,866 | 2010-11-03 | ||
| PCT/EP2011/069369 WO2012059561A1 (en) | 2010-11-03 | 2011-11-03 | Anti c-met antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013010688A2 true BR112013010688A2 (pt) | 2016-08-09 |
| BR112013010688B1 BR112013010688B1 (pt) | 2020-11-17 |
Family
ID=44906140
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013010688-3A BR112013010688B1 (pt) | 2010-11-03 | 2011-11-03 | combinações de anticorpos c-met |
| BR122014027420-3A BR122014027420A2 (pt) | 2010-11-03 | 2011-11-03 | Anticorpos anti c-met |
| BR112013010687A BR112013010687A2 (pt) | 2010-11-03 | 2011-11-03 | combinações de anticorpos c-met |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122014027420-3A BR122014027420A2 (pt) | 2010-11-03 | 2011-11-03 | Anticorpos anti c-met |
| BR112013010687A BR112013010687A2 (pt) | 2010-11-03 | 2011-11-03 | combinações de anticorpos c-met |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US8637027B2 (pt) |
| EP (3) | EP2635602B1 (pt) |
| JP (3) | JP5857060B2 (pt) |
| CN (2) | CN103562223B (pt) |
| AU (3) | AU2011325098B2 (pt) |
| BR (3) | BR112013010688B1 (pt) |
| CA (2) | CA2816745C (pt) |
| DK (1) | DK2635602T3 (pt) |
| ES (1) | ES2594493T3 (pt) |
| IL (2) | IL226112B (pt) |
| RU (2) | RU2608644C2 (pt) |
| WO (2) | WO2012059561A1 (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| EP2143441A1 (en) | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| AU2011325098B2 (en) | 2010-11-03 | 2016-07-14 | Argen-X N.V. | c-Met antibody combinations |
| KR20130036993A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| PT2768857T (pt) * | 2011-10-19 | 2020-01-27 | Novimmune Sa | Métodos para purificar anticorpos |
| EP2773660A2 (en) * | 2011-11-03 | 2014-09-10 | Argen-X B.V. | Chimeric human-camel antigens and their use |
| US20130129718A1 (en) | 2011-11-21 | 2013-05-23 | Genentech, Inc. | Purification of anti-c-met antibodies |
| WO2013079973A1 (en) * | 2011-12-02 | 2013-06-06 | Di Cara Danielle Marie | Antibodies against hgf - receptor and uses |
| EP2807189B1 (en) | 2012-01-23 | 2019-03-20 | Ablynx N.V. | Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| US9931400B2 (en) | 2012-09-12 | 2018-04-03 | Samsung Electronics Co., Ltd. | Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| US9535055B2 (en) * | 2013-03-28 | 2017-01-03 | Samsung Electronics Co., Ltd. | Marker for determining effects of anti-c-Met antibody and method of determining effects of anti-c-Met antibody using the marker |
| EP2786765B1 (en) * | 2013-04-01 | 2018-10-03 | Samsung Electronics Co., Ltd. | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor |
| KR102139607B1 (ko) * | 2013-04-01 | 2020-07-30 | 삼성전자주식회사 | 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물 |
| US10214593B2 (en) | 2013-04-02 | 2019-02-26 | Samsung Electronics Co., Ltd. | Anti-idiotype antibody against anti-c-MET antibody |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| EP2992019B1 (en) * | 2013-04-30 | 2019-03-06 | Agency For Science, Technology And Research | Mab 2 anti-met antibody |
| KR102186363B1 (ko) * | 2013-09-06 | 2020-12-04 | 삼성전자주식회사 | c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102192591B1 (ko) * | 2013-09-09 | 2020-12-18 | 삼성전자주식회사 | c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물 |
| ES2898343T3 (es) * | 2014-07-29 | 2022-03-07 | Wellmarker Bio Co Ltd | Inhibidores de MET e IGSF1 para el tratamiento de cáncer de estómago y de pulmón |
| WO2016042412A1 (en) * | 2014-09-16 | 2016-03-24 | Symphogen A/S | Anti-met antibodies and compositions |
| US20180057595A1 (en) | 2015-03-16 | 2018-03-01 | Celldex Therapeutics, Inc. | Anti-MET Antibodies and Methods of Use Thereof |
| GB201611123D0 (en) * | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| WO2018057955A1 (en) * | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| WO2018221969A1 (en) * | 2017-05-30 | 2018-12-06 | Chong Kun Dang Pharmaceutical Corp. | A novel anti-c-met antibody and use thereof |
| AU2018278730B2 (en) | 2017-05-30 | 2021-02-04 | Chong Kun Dang Pharmaceutical Corp. | A novel anti-c-Met antibody and use thereof |
| CN111093696B (zh) * | 2017-07-17 | 2023-10-27 | 詹森生物科技公司 | 抗iii型纤连蛋白结构域的抗原结合区及其使用方法 |
| CN109771642B (zh) * | 2017-11-13 | 2022-09-20 | 同济大学苏州研究院 | c-MET激动型抗体及其用途 |
| WO2020068752A1 (en) * | 2018-09-27 | 2020-04-02 | Celgene Corporation | SIRPα BINDING PROTEINS AND METHODS OF USE THEREOF |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| EP4031574A1 (en) | 2019-09-16 | 2022-07-27 | Regeneron Pharmaceuticals, Inc. | Radiolabeled met binding proteins for immuno-pet imaging |
| EP4320152A1 (en) | 2021-04-08 | 2024-02-14 | Byondis B.V. | Anti-c-met antibodies and antibody-drug conjugates |
| WO2023034569A1 (en) * | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
| EP0805203B1 (en) | 1992-09-18 | 2007-08-01 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Medical use of an antibody or antibody fragment against the extracellular domain of Met for the prevention of metastasis |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| CA2258153C (en) | 1996-07-03 | 2004-08-17 | Genentech, Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
| ITMI20031127A1 (it) | 2003-06-05 | 2004-12-06 | Uni Degli Studi Del Piemont E Orientale Am | Anticorpi anti-hgf-r e loro uso |
| CN100538364C (zh) * | 2003-06-06 | 2009-09-09 | 健泰科生物技术公司 | 调节HGFβ链和C-MET的相互作用 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| KR100556660B1 (ko) * | 2003-11-11 | 2006-03-10 | 국립암센터 | Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
| KR101195291B1 (ko) | 2003-12-11 | 2012-10-26 | 제넨테크, 인크. | Ｃ－ｍｅｔ 이량체화 및 활성화를 억제하는 방법 및조성물 |
| AU2005267720B2 (en) | 2004-08-05 | 2012-02-23 | Genentech, Inc. | Humanized anti-cmet antagonists |
| WO2007110698A2 (en) | 2005-11-16 | 2007-10-04 | Fariba Nayeri | Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors |
| CA2638889C (en) | 2006-02-06 | 2015-06-02 | Metheresis Translational Research S.A. | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| MX2008012485A (es) | 2006-03-30 | 2008-10-10 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de c-met. |
| FR2906533B1 (fr) | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US20090191580A1 (en) | 2007-07-19 | 2009-07-30 | Eisai R & D Management Co., Ltd. | METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE |
| US7892770B2 (en) | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| IL198545A0 (en) | 2008-05-14 | 2011-07-31 | Metheresis Translational Res Sa | High affinity binding site of hgfr and methods for identification of antagonists thereof |
| US8455623B2 (en) | 2008-05-21 | 2013-06-04 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| WO2009145606A1 (en) | 2008-05-28 | 2009-12-03 | U-Protein Express B.V. | Method for the production of proteins or protein fragments |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| WO2010005965A1 (en) | 2008-07-08 | 2010-01-14 | Aronchick Craig A | Colonic purgative formulations and methods of using the same |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| AU2011325098B2 (en) | 2010-11-03 | 2016-07-14 | Argen-X N.V. | c-Met antibody combinations |
-
2011
- 2011-11-03 AU AU2011325098A patent/AU2011325098B2/en not_active Ceased
- 2011-11-03 EP EP11778618.6A patent/EP2635602B1/en active Active
- 2011-11-03 EP EP11778887.7A patent/EP2635603B1/en active Active
- 2011-11-03 JP JP2013537138A patent/JP5857060B2/ja active Active
- 2011-11-03 ES ES11778618.6T patent/ES2594493T3/es active Active
- 2011-11-03 WO PCT/EP2011/069369 patent/WO2012059561A1/en active Application Filing
- 2011-11-03 JP JP2013537139A patent/JP2013545738A/ja active Pending
- 2011-11-03 US US13/288,566 patent/US8637027B2/en active Active
- 2011-11-03 US US13/288,587 patent/US9688773B2/en active Active
- 2011-11-03 WO PCT/EP2011/069372 patent/WO2012059562A1/en active Application Filing
- 2011-11-03 CN CN201180052993.1A patent/CN103562223B/zh active Active
- 2011-11-03 RU RU2013125459A patent/RU2608644C2/ru active
- 2011-11-03 EP EP16187257.7A patent/EP3165538A1/en not_active Withdrawn
- 2011-11-03 RU RU2013125457/10A patent/RU2013125457A/ru unknown
- 2011-11-03 BR BR112013010688-3A patent/BR112013010688B1/pt active IP Right Grant
- 2011-11-03 CA CA2816745A patent/CA2816745C/en active Active
- 2011-11-03 BR BR122014027420-3A patent/BR122014027420A2/pt not_active Application Discontinuation
- 2011-11-03 BR BR112013010687A patent/BR112013010687A2/pt not_active IP Right Cessation
- 2011-11-03 CN CN201180063338.6A patent/CN103764678A/zh active Pending
- 2011-11-03 DK DK11778618.6T patent/DK2635602T3/en active
- 2011-11-03 AU AU2011325097A patent/AU2011325097B2/en active Active
- 2011-11-03 CA CA2816919A patent/CA2816919A1/en not_active Abandoned
-
2013
- 2013-05-02 IL IL226112A patent/IL226112B/en active IP Right Grant
- 2013-05-02 IL IL226113A patent/IL226113A0/en unknown
- 2013-12-06 US US14/098,849 patent/US9884917B2/en active Active
-
2015
- 2015-02-17 US US14/624,216 patent/US9631027B2/en active Active
- 2015-02-17 US US14/624,193 patent/US9688774B2/en active Active
- 2015-08-07 AU AU2015210420A patent/AU2015210420B2/en active Active
- 2015-09-09 JP JP2015177202A patent/JP2016034957A/ja active Pending
-
2017
- 2017-05-16 US US15/596,890 patent/US20170349667A1/en not_active Abandoned
- 2017-12-26 US US15/854,312 patent/US10676535B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2019011I1 (lt) | CGRP antikūnai | |
| BR112013010688A2 (pt) | anticorpos anti c-met | |
| BR112012030311A2 (pt) | anticorpo | |
| CO7020871A2 (es) | Anticuerpos anti-il-36r | |
| CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
| DK2934584T3 (da) | Anti-gdf15-antistoffer | |
| DK2850101T3 (da) | Anti-FcRn-antistoffer | |
| DK2521736T3 (da) | Humaniserede antistoffer | |
| DK3284754T3 (da) | Anti-cd38-antistoffer | |
| BR112012028556A2 (pt) | Indóis | |
| DE102011100241A8 (de) | Nitridhalbleiterbauteil | |
| CR20130111A (es) | Triazina-oxidiazoles | |
| DE10170954T8 (de) | Mikrowellendruckgarer | |
| CR20140127A (es) | Anticuerpo anti-abtcr | |
| DE112011104226A5 (de) | Käfigmutter | |
| CO6791565A2 (es) | Anticuerpos anti-notch1 | |
| DE102011117046A8 (de) | Doppelkupplungswindungsgetriebe | |
| DE112011102080A5 (de) | Kupplungszentralausrücker | |
| DK2442899T3 (da) | Rotorskive | |
| DE102011002623A8 (de) | Ventilsteuerzeitversteller | |
| DK2828292T3 (da) | Jcv-neutraliserende antistoffer | |
| DE112011102711A5 (de) | Hydrostataktor | |
| DK2448659T3 (da) | Rotorskive | |
| DK2447426T3 (da) | Vaske-WC | |
| DK3521315T3 (da) | Anti-transglutaminase-2-antistoffer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: ARGEN-X BV (NL) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: ARGEN-X N.V. (NL) |
|
| B25D | Requested change of name of applicant approved |
Owner name: ARGENX SE (NL) |
|
| B25A | Requested transfer of rights approved |
Owner name: ARGENX BVBA (BE) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2011, OBSERVADAS AS CONDICOES LEGAIS. |